Nuvaxovid Vaccine Safety Profile in Australia
Author Information
Author(s): Hazel Clothier, Claire Parker, John Mallard, Paul Effler, Lauren Bloomfield, Dale Carcione, Jim Buttery
Primary Institution: Melbourne Children’s Campus, Melbourne, Australia
Hypothesis
What is the safety profile of the Nuvaxovid vaccine in a real-world setting after over 100,000 doses administered?
Conclusion
The analysis affirmed the safety profile of Nuvaxovid, showing mostly mild adverse events and no deaths attributable to vaccination.
Supporting Evidence
- 356 adverse event reports were received following 102,946 doses administered.
- Rates of adverse events were higher after the first dose compared to the second.
- Serious adverse events included 94 cases of chest pain and two cases of myocarditis.
Takeaway
The Nuvaxovid vaccine is mostly safe, with only mild side effects reported after many doses given in Australia.
Methodology
A retrospective observational analysis of adverse events following immunisation reported to SAFEVAC from 14 February 2022 to 30 June 2023.
Potential Biases
Potential under-reporting and biases associated with spontaneous reporting systems.
Limitations
The study was based on enhanced spontaneous surveillance data, which may incur biases such as under-reporting.
Participant Demographics
Participants included individuals aged 6–97 years, with a higher reporting rate in females.
Statistical Information
P-Value
p=0.0008
Confidence Interval
95% CI: 1.2–2.0
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website